Evidence map›Paper›PMID 34145105›Full record

ArticleThe Indian journal of medical research2020

Effectiveness of isoniazid preventive therapy on incidence of tuberculosis among HIV-infected adults in programme setting.

C Padmapriyadarsini, L Sekar, Devarajulu Reddy, Anandha Chitra, N Poornagangadevi, M Selvaraj, P K Bhavani, S N Mothi, K Nandagopal, S Vennila and 5 more

Open access · diamondAbstract read
In one paragraph

Article in The Indian journal of medical research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
0.0field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Observational
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 1 country.

C PadmapriyadarsiniDepartment of Clincial Research, ICMR-National Institute for Research in Tuberculosis, Chennai, India.
L SekarDepartment of Statistics, ICMR-National Institute for Research in Tuberculosis, Chennai, India.
Devarajulu ReddyDepartment of Clincial Research, ICMR-National Institute for Research in Tuberculosis, Chennai, India.
Anandha ChitraGovernment Rajaji Medical College & Hospital, Madurai, India.
N PoornagangadeviDepartment of Clincial Research, ICMR-National Institute for Research in Tuberculosis, Chennai, India.
M SelvarajART Centre, Government Vellore Medical College & Hospital, Vellore, India.
P K BhavaniDepartment of Clincial Research, ICMR-National Institute for Research in Tuberculosis, Chennai, India.
S N MothiPaediatric ART Centre, Ashakirana Hospital, Mysuru, Karnataka, India.
K NandagopalNodal ART Centre, Government Kilpauk Medical College & Hospital, Chennai, India.
S VennilaART Centre, Government Vellore Medical College & Hospital, Vellore, India.
M TamizhselvanDepartment of Statistics, ICMR-National Institute for Research in Tuberculosis, Chennai, India.
J MaheshmanishaGovernment District Hospital, Tiruvallur, Tamil Nadu, India.
Upasna AgarwalNodal ART Centre, National Institute for Tuberculosis & Respiratory Diseases, New Delhi, India.
B B RewariCare, Support & Treatment Division, National AIDS Control Organization, New Delhi, India.
Soumya SwaminathanDepartment of Clincial Research, ICMR-National Institute for Research in Tuberculosis, Chennai, India.
National Institute of Research in Tuberculosis · INGovernment Vellore Medical College · INAsha Hospital · INGovernment Kilpauk Medical College · INGovernment Rajaji Hospital · INNational AIDS Control Organisation · INNational Tuberculosis Institute · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND &

objectivesAs India and other developing countries are scaling up isoniazid preventive therapy (IPT) for people living with HIV (PLHIV) in their national programmes, we studied the feasibility and performance of IPT in terms of treatment adherence, outcome and post-treatment effect when given under programmatic settings.

methodsA multicentre, prospective pilot study was initiated among adults living with HIV on isoniazid 300 mg with pyridoxine 50 mg after ruling out active tuberculosis (TB). Symptom review and counselling were done monthly during IPT and for six-month post-IPT. The TB incidence rate was calculated and risk factors were identified.

resultsAmong 4528 adults living with HIV who initiated IPT, 4015 (89%) successfully completed IPT. IPT was terminated in 121 adults (3%) due to grade 2 or above adverse events. Twenty five PLHIVs developed TB while on IPT. The incidence of TB while on IPT was 1.17/100 person-years (p-y) [95% confidence interval (CI) 0.8-1.73] as compared to TB incidence of 2.42/100 p-y (95% CI 1.90-3.10) during the pre-IPT period at these centres (P=0.017). The incidence of TB post-IPT was 0.64/100 p-y (95% CI 0.04-1.12). No single factor was significantly associated with the development of TB. INTERPRETATION &

conclusionsUnder programmatic settings, completion of IPT treatment was high, adverse events minimal with good post-treatment protection. After ruling out TB, IPT should be offered to all PLHIVs, irrespective of their antiretroviral therapy (ART) status. Scaling-up of IPT services including active case finding, periodic counselling on adherence and re-training of ART staff should be prioritized to reduce the TB burden in this community.

Indexed as

HIV InfectionsTuberculosisAdultAntitubercular AgentsHumansIncidenceIndiaIsoniazidPilot ProjectsProspective StudiesAntitubercular AgentsIsoniazidAntiretroviral therapyIPTpeople living with HIVprogrammatic settingstuberculosis prevention

Identifiers

PMID34145105
PMCPMC8224160
OpenAlexW3171101348

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.